2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2475 Donor DC3 cells promote differentiation and expansion of CD103⁺CD8⁺ tissue-resident T memory cells that contribute to sclerotic skin GVHD pathogenesis in humans

Weijia Fu, MD, Yuankun Zhang2, Moqian Zheng3, Qinjian Li, MS4, Paul J Martin, MD5, Ryotaro Nakamura, MD6, Jianmin Yang7, Defu Zeng, MD, PhD8
1 Changhai Hospital, Shanghai, Shanghai, China, City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 Changhai Hospital, Shanghai, Shanghai, China
8 City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States

Introduction:

Dendritic cell subset 3 (DC3) is a distinct CD1c⁺ myeloid population with inflammatory and tissue-remodeling properties, and epiregulin (EREG)-expressing DC3 has been proposed to play an important role in fibrotic disorders and sclerotic graft-versus-host disease (GVHD). Transplantation of G-CSF-mobilized peripheral blood hematopoietic stem cells (PBHSC) is associated with more severe sclerotic GVHD. CD8+ Trm cells were also reported to augment fibrosis. However, the role of DC3 and CD8+ Trm cells in sclerotic GVHD pathogenesis in patients given G-CSF-mobilized PBHSC remains unclear.

 

Methods:

Peripheral blood mononuclear cells (PBMNC) were collected from patients with sclerotic GVHD, non-sclerotic GVHD, or No-GVHD and healthy control.  DC3 were identified by flow cytometry as CD45⁺Lin⁻HLA-DR⁺CD11c⁺CD123⁻CD88⁻CD1c⁺CD163⁺CD5⁻, DC2 were defined as CD1c⁺CD163⁻, and DC1 as CD1c⁻CD141⁺CLEC9A⁺ cells.  For functional studies, DC2 and DC3 were sorted from lineage-depleted healthy-donor PBMNC and activated with poly(I:C), R848, and lipopolysaccharide. Activated DC subsets were cocultured with negatively selected autologous T cells for 5 days, followed by assessment of CD103 and CD69 expression in CD8⁺ and CD4⁺ T cells. In paired exploratory samples, circulating pro-DC3 were compared before and after granulocyte colony-stimulating factor (G-CSF) mobilization. Skin tissues of sclerotic GVHD and non-GVHD was subjected to spatial transcriptomic analysis.

 

Results:

There was a significant increase of CD34⁺CD38⁺CD371⁺ DC3 precursors among donor G-CSF-mobilized PBHSC. Circulating DC3 frequency was significantly increased in patients with sclerotic GVHD compared with patients with Non-sclerotic GVHD or No-GVHD, but the changes in DC1 or DC2 were not significant. In functional coculture assays, as compared with DC2, DC3 induced significantly higher frequency of CD103⁺CD8⁺ T cells and CD103+CD69+CD8+ T cells. Consistently, the frequencies of CD103+CD69+CD8+Trm cells was markedly increased in the sclerotic GVHD skin tissues as compared to non-sclerotic GVHD skin tissues. Spatial transcriptomic analysis of the patient skin tissues with or without sclerotic GVHD is ongoing.

 

Conclusions:

G-CSF-mobilized PBHSC contains higher frequencies of DC3 precursors in consistency with higher frequencies of DC3 among PBMNC from patients with sclerotic skin GVHD. DC3 preferentially promote CD103⁺CD8⁺ TRM differentiation. These findings support a potential DC3–CD103+CD8⁺ Trm axis in GVHD pathogenesis. Ongoing studies will dissect how circulating and tissue-infiltrating DC3 and CD103+CD8+ Trm cells mediate and sustain sclerotic skin GVHD.

Weijia Fu, MD: No relevant conflicts of interest to declare.